References
- Maier S, Barcutean L, Andone S, Manu D, Sarmasan E. Bajko Z, et al. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis. Int J Mol Sci. 2023;24(5):4375. DOI: 10.3390/ijms24054375
- Dutta R, Trapp BD. Relapsing and Progressive Forms of Multiple Sclerosis: Insights from Pathology. Curr Opin Neurol. 2014;27(3):271-278. DOI: 10.1097/WCO.0000000000000094
- Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions. Neurology. 2014;83(3):278-286. DOI: 10.1212/WNL.0000000000000560
- Ebers GC. Natural History of Primary Progressive Multiple Sclerosis. Mult Scler. 2004;10(suppl 1):S8-S13. DOI: 10.1177/135245850401000103
- Syed YY. Ocrelizumab: A Review in Multiple Sclerosis. CNS Drugs. 2018;32(9):883-890. DOI: 10.1007/s40263-018-0568-7
- Maier S, Motataianu A, Barcutean L, Balint A, Hutanu A, Bajko Z, et al.; Balasa, R. Interferon-β 1a, an Immunomodulator in Relapsing-Remitting Multiple Sclerosis Patients. The Effect on Pro-inflammatory Cytokines. Farmacia. 2020;68(1):65-75. DOI: 10.31925/farmacia.2020.1.10
- Michel L, Touil H, Pikor NB, Gommerman JL, Prat A, Bar-Or A. B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Front Immunol, 2015;6:636. DOI: 10.3389/fimmu.2015.00636
- Lamb YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022;82:323-334. DOI: 10.1007/s40265-022-01672-9
- Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D. et al. ECTRIMS/EAN Guideline on the Pharmacological Treatment of People with Multiple Sclerosis. Mult Scler J. 2018;24(2):96-120. DOI: 10.1177/1352458517751049
- Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928. DOI: 10.1101/cshperspect.a028928
- Compston A, Coles A. Multiple Sclerosis. Lancet. 2008;372:1502-1517. doi.org/10.1016/S0140-6736(08)61620-7 DOI: 10.1016/S0140-6736(08)61620-7
- Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, University of British Columbia MS Clinic Neurologists. Early Onset Multiple Sclerosis: A Longitudinal Study. Neurology. 2002;59:1006-1010. DOI: 10.1212/WNL.59.7.1006
- Lassmann H, Bruck W, Lucchinetti CF. The Immunopathology of Multiple Sclerosis: An Overview. Brain Pathol. 2007;17(2):210-218. DOI: 10.1111/j.1750-3639.2007.00064.x
- Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple Sclerosis-A Quiet Revolution. Nat Rev Neurol. 2015;11(3):134-142. DOI: 10.1038/nrneurol.2015.14
- Balasa R, Maier S, Barcutean L, Stoian A, Motataianu A. The Direct Deleterious Effect of Th17 Cells in the Nervous System Compartment in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: One Possible Link between Neuroinflammation and Neurodegeneration. Rev Romana Med Lab. 2020;28(1):9-17. DOI: 10.2478/rrlm-2020-0005
- Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Eng J Med. 2017;376(3):221-234. DOI: 10.1056/NEJMoa1601277
- Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220. DOI: 10.1056/NEJMoa1606468
- Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA. Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers. Neurotherapeutics. 2022;19(4):1216-1228. DOI: 10.1007/s13311-022-01252-5
- Cross A, Bennett J, von Büdingen HC, Carruthers R, Edwards K, Fallis R, et al. Ocrelizumab Treatment Reduced Levels of Neurofilament Light Chain and Numbers of B Cells in the Cerebrospinal Fluid of Patients with Relapsing Multiple Sclerosis in the OBOE Study (S56.008). Neurology. 2019;92(suppl 15):S56.008. DOI: 10.1212/WNL.92.15_supplement.S56.008. DOI: 10.1212/WNL.92.15_supplement.S56.008
- Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, et al. Chronic White Matter Lesion Activity Predicts Clinical Progression in Primary Progressive Multiple Sclerosis. Brain. 2019;142(9):2787-2799. DOI: 10.1093/brain/awz212
- Ferreira-Atuesta C, Reyes S, Giovanonni G, Gnanapavan S. The Evolution of Neurofilament Light Chain in Multiple Sclerosis. Front Neurosci. 2021;15:642384. DOI: 10.3389/fnins.2021.642384
- Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament Light Chain as a Biomarker in Neurological Disorders. J. Neurol. Neurosurg. Psychiatry. 2019;90(8):870-881. DOI: 10.1136/jnnp-2018-320106
- Gnanapavan S, Giovannoni G. Developing Biomarkers for MS. Curr Top Behav Neurosci. 2015;26:179-194. DOI: 10.1007/7854_2014_362
- Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, Vrethem M, et al. Axonal Damage in Relapsing Multiple Sclerosis Is Markedly Reduced by Natalizumab. Ann Neurol. 2011;69(1):83-89. DOI: 10.1002/ana.22247
- Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria. The Lancet Neurol. 2018;17(2):162-173. DOI: 10.1016/S1474-4422(17)30470-2
- Kurtzke JF. Rating Neurologic Impairment in Multiple Sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452. DOI: 10.1212/WNL.33.11.1444
- Paul A, Comabella M, Gandhi R. Biomarkers in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2019;9(3):a029058. DOI: 10.1101/cshperspect.a029058
- Bărcuţean LI, Romaniuc A, Maier S, Bajko Z, Moţăţăianu A.; Hutanu A et al. Clinical and Serological Biomarkers of Treatment’s Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade. CNS Neurol. Disord. Drug Targets. 2018;17(10):780-792. DOI: 10.2174/18715273176 66180917095256
- Balasa R, Maier S, Voidazan S, Hutanu A, Bajko Z, Motataianu A, et al. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response. CNS Neurol. Disord. Drug Targets. 2017;16(1):93-101. DOI: 10.2174/1871527315666 160615110739
- Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal Transection in the Lesions of Multiple Sclerosis. N Engl J Med. 1998;338(5):278-285. DOI: 10.1056/NEJM199801293380502
- De Stefano N, Narayanan S, Francis SJ, Smith S, Mortilla M, Carmela Tartaglia M, et al. Diffuse Axonal and Tissue Injury in Patients with Multiple Sclerosis with Low Cerebral Lesion Load and No Disability. Arch Neurol. 2002;59(10):1565-1571. DOI: 10.1001/archneur.59.10.1565
- Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A.; et al. Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis. Brain. 2003;126(Pt2):433-437. DOI: 10.1093/brain/awg038
- Gaetani L, Eusebi P, Mancini A, Gentili L, Borrelli A, Parnetti L, et al. Cerebrospinal Fluid Neurofilament Light Chain Predicts Disease Activity after the First Demyelinating Event Suggestive of Multiple Sclerosis. Mult Scler Relat Disord. 2019;35:228-232. DOI: 10.1016/j.msard.2019.07.025
- Domingues RB, Fernandes GBP, Leite FBVDM, Senne C. Neurofilament Light Chain in the Assessment of Patients with Multiple Sclerosis. Arq. Neuropsiquiatr. 2019;77(6):436-441. DOI: 10.1590/0004-282x20190060
- Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, et al. Blood Neurofilament Light Levels Predict Non-relapsing Progression Following Anti-CD20 Therapy in Relapsing and Primary Progressive Multiple Sclerosis: Findings from the Ocrelizumab Randomised, Double-blind Phase 3 Clinical Trials. EbioMedicine. 2023;93:104662. DOI: 10.1016/j.ebiom.2023.104662
- Abbadessa G, Miele G, Maida E, Vanore E, Cipriano L, Coppola C, et al. Immunomodulatory Effects of Ocrelizumab and Candidate Biomarkers for Monitoring Treatment Response in Multiple Sclerosis. Mult Scler. 2023;29(7):779-788. DOI: 10.1177/13524585221147635
- Romme Christensen J, Komori M, von Essen MR, Ratzer R, Börnsen L, Bielekova B, et al. CSF Inflammatory Biomarkers Responsive to Treatment in Progressive Multiple Sclerosis Capture Residual Inflammation Associated with Axonal Damage. Mult Scler. 2019; 25(7):937-946. DOI: 10.1177/1352458518774880
- Thebault S, Bose G, Booth R, Freedman MS. Serum Neurofilament Light in MS: The First True Blood-based Biomarker? Mult Scler. 2022;28(10):1491-1497. DOI: 10.1177/1352458521993066
- Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, et al. Serum Neurofilament Light Chain in Early Relapsing Remitting MS Is Increased and Correlates with CSF Levels and with MRI Measures of Disease Severity. Mult Scler. 2016;22(12):1550-1559. DOI: 10.1177/1352458515623365
- Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, et al. Comparison of Three Analytical Platforms for Quantification of the Neurofilament Light Chain in Blood Samples: ELISA, Electrochemiluminescence Immunoassay and Simoa. Clin Chem Lab Med. 2016;54(10):1655-1661. DOI: 10.1515/cclm-2015-1195
- Mathias A, Pantazou V, Perriot S, Canales M, Jones S, Oberholster L, et al. Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(2):e200084. DOI: 10.1212/NXI.0000000000200084
- Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, et al. Ocrelizumab Efficacy in Subgroups of Patients with Relapsing Multiple Sclerosis. J Neurol. 2019;266(5):1182-1193. DOI: 10.1007/s00415-019-09248-6
- Cellerino M, Boffa G, Lapucci C, Tazza F, Sbragia E, Mancuso E, et al. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. Neurotherapeutics. 2021;18(4):2579-2588. DOI: 10.1007/s13311-021-01104-8
- Curran C, Vaitaitis G, Waid D, Volmer T, Alverez E, Wagner DH. Ocrevus Reduces TH40 Cells, a Biomarker of Systemic Inflammation, in Relapsing Multiple Sclerosis (RMS) and in Progressive Multiple Sclerosis (PMS). J Neuroimmunol. 2023;374:578008. DOI: 10.1016/j.jneuroim.2022.578008
- Mancinelli CR, Rossi N, Capra R. Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology. Ther Clin Risk Manag. 2021;17:765-776. DOI: 10.2147/TCRM.S282390
- Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in Multiple Sclerosis. WIREs Mech Dis. 2023;15(1):e1583. DOI: 10.1002/wsbm.1583
- Lassmann H. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Front Immunol. 2019;10:3116. DOI: 10.3389/fimmu.2018.03116
- Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Ann Rev Neurosci. 2008;31:247-269. DOI: 10.1146/annurev.neuro.30.051606.094313
- Mahad DH, Trapp BD, Lassmann H. Pathological Mechanisms in Progressive Multiple Sclerosis. Lancet Neurol. 2015;14(2):183-93. DOI: 10.1016/S1474-4422(14)70256-X
- Stadelmann C. Multiple sclerosis as a neurodegenerative disease: Pathology, mechanisms and therapeutic implications. Curr Opin Neurol. 2011;24(3):224-229. DOI: 10.1097/WCO.0b013e328346056f